Nafiseh Ghazanfari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nafiseh Ghazanfari has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aboud Tahanis
Department of Neurosurgery, Houston Methodist Research Institute, Houston, USA
1 shared publication - Belen Pascual
Department of Neurology, Houston Methodist, Houston, USA
1 shared publication - David R. Beers
Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX 77030, USA
1 shared publication - John D. Patterson
Department of Neurosurgery, Houston Methodist Research Institute, Houston, USA
1 shared publication - Joseph C. Masdeu
Nantz National Alzheimer Center, Houston Methodist Neurological Institute and Weill Cornell Medicine, Houston, TX 77030, USA
1 shared publication - Kanayo Ikeneme
Department of Neuroradiology, Houston Methodist Research Institute, Houston, USA
1 shared publication
Latest Publications
- 30 July 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (1) , 505-517
Translocator protein (TSPO) positron emission tomography imaging and expression in patients with brain metastases
Purpose 18 kDa translocator protein (TSPO) is a biomarker for inflammatory conditions. However, full kinetic positron emission tomography (PET) modeling has rarely been used to quantify brain tumors, and it has never been used in brain metastases (BMs). This proof-of-principle study quantified TSPO expression using full kinetic modeling in patients with BMs from various types of peripheral primary tumors. Methods Nine adult patients with BMs and 12 healthy volunteers (HVs) took part in the study. The total distribution volume (VT) of 11C-ER176 was calculated with a two-tissue compartment model (2TCM) and metabolite-corrected arterial input function in the BMs and in the rest of the brain. Immunohistochemistry (IHC) and single-cell RNAseq database were used to quantify TSPO expression in vitro. The VT values of the hemisphere contralateral to the BMs were compared to the cortical values of HVs. Results 11C-ER176 uptake was increased in BMs compared with the rest of the brain of each participant. The BM time-activity curves were well-fitted by the 2TCM, and the resulting VT (range 3.2–13 mL/cm3) was identified with precision (standard error generally < 5%). The rate constant mostly affected by the integrity of the blood–brain barrier (BBB) (K1) was similar between the BMs and the contralateral hemisphere. TSPO expression was detected by IHC in tumor regions and variably in microglia/macrophages, a finding largely corroborated by single-cell RNAseq database. The average VT of the rest of the brain in BM patients was significantly lower than in HVs, which may have been due to immunosuppressive therapy. Conclusion In this pilot study, full kinetic modeling quantified TSPO expression in BMs with good fit and precision. The kinetic modeling outcome parameters and the TSPO expression levels in vitro suggest that 11C-ER176 binding was largely specific and not significantly affected by disruption of the BBB.
- 30 July 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (1) , 505-517
Translocator protein (TSPO) positron emission tomography imaging and expression in patients with brain metastases
Purpose 18 kDa translocator protein (TSPO) is a biomarker for inflammatory conditions. However, full kinetic positron emission tomography (PET) modeling has rarely been used to quantify brain tumors, and it has never been used in brain metastases (BMs). This proof-of-principle study quantified TSPO expression using full kinetic modeling in patients with BMs from various types of peripheral primary tumors. Methods Nine adult patients with BMs and 12 healthy volunteers (HVs) took part in the study. The total distribution volume (VT) of 11C-ER176 was calculated with a two-tissue compartment model (2TCM) and metabolite-corrected arterial input function in the BMs and in the rest of the brain. Immunohistochemistry (IHC) and single-cell RNAseq database were used to quantify TSPO expression in vitro. The VT values of the hemisphere contralateral to the BMs were compared to the cortical values of HVs. Results 11C-ER176 uptake was increased in BMs compared with the rest of the brain of each participant. The BM time-activity curves were well-fitted by the 2TCM, and the resulting VT (range 3.2–13 mL/cm3) was identified with precision (standard error generally < 5%). The rate constant mostly affected by the integrity of the blood–brain barrier (BBB) (K1) was similar between the BMs and the contralateral hemisphere. TSPO expression was detected by IHC in tumor regions and variably in microglia/macrophages, a finding largely corroborated by single-cell RNAseq database. The average VT of the rest of the brain in BM patients was significantly lower than in HVs, which may have been due to immunosuppressive therapy. Conclusion In this pilot study, full kinetic modeling quantified TSPO expression in BMs with good fit and precision. The kinetic modeling outcome parameters and the TSPO expression levels in vitro suggest that 11C-ER176 binding was largely specific and not significantly affected by disruption of the BBB.